PR Newswire Clinical TrialsOriginal article
Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 2026
Data ReadoutpositiveInvikafusp alfaTRODELVYPositive
AI Analysis
Summary
Interim Phase 2 results from the STARt-002 study combining invikafusp alfa and TRODELVY have been selected for oral presentation at SITC 2026. This is the first clinical study to combine a Vβ6-selective T-cell agonist with an ADC.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Interim Phase 2 results from STARt-002 combination study selected for oral presentation
Importance:6/10
Sentiment:
0.60
Phase 2Combination therapyT-cell agonistADCSITC 2026Oral presentation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 2, 2026 11:00 AM